Myeloma Patients Europe appoints joint CEOs

Myeloma Patients Europe (MPE) is pleased to announce that Katie Joyner and Kate Morgan have been appointed as joint Chief Executive Officers (CEO). The MPE Board of Directors unanimously made this decision based on the impressive work and leadership both have shown during the transition period following the stepping down of founding CEO, Ananda Plate.

Job offer – Medical and Scientific officer

Job Title: Medical and Scientific Officer Position Type: Mini-job Probation period: six months Location: Germany Gross salary: 520 € monthly (approximately 43 hours a month) Tasks and core responsibilities (non-exhaustive and subject to change depending on the needs of the organisation). As Medical and Scientific officer, you will work in the Medical Education and Scientific Engagement area. You will assist the Head of Medical Education and Scientific Engagement with the following activities:   European Myeloma and…

Volunteers of AMEN protesting outside the “Health Basket” Committee conference to include Daratumumab for NDMM patients (December 2021)

Daratumumab approved for first line treatment in Israel

Funding for Daratumumab was recently approved in Israel for the treatment of newly diagnosed multiple myeloma (NDMM) patients in first line treatment, in large part thanks to a strong collaboration between the MPE Israeli member, AMEN, with local haematologists and pharmaceutical companies in Israel.  “Health Basket” Each year, the Israel Ministry of Health nominates a Health Committee to discuss and recommend approval and extension for a new “health basket,” which includes all the services, medications, supplies, and…

Study shows the importance of vaccination for myeloma patients

Influenza (i.e. “flu”) and pneumococcal vaccinations positively impact the outcomes of myeloma patients. This is the central conclusion in the article Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma (MM) Patients: Influenza and Pneumococcal Vaccination in MM, published in Clinical Lymphoma, Myeloma and Leukaemia. The article outlines an analysis of data gathered from INSIGHT-MM, a global real-world study involving myeloma patients, looking at influenza and pneumococcal vaccination rates of patients and…

2022: Year in Review

Myeloma Patients Europe’s (MPE) 2022 Year in Review is snapshot of the major accomplishments from the past year. In this report, you’ll read about MPE’s activities and key accomplishments to empower our members, educate the patient community, shape drug development, address gaps in patient evidence, and increase access to innovative treatments. We look forward to the continued growth and evolution of these initiatives in the years ahead as we continue our efforts to improve patient treatment, care,…

Myeloma diagnosis can take over 5 months and require more than 4 medical consultations with more than 3 different specialists

Brussels, 27 September 2022 – For some European myeloma patients, their diagnosis can take over 5 months, require more than 4 medical consultations and involve visits to at least 3 different medical specialists. These are some of the findings of pan-European research conducted by Myeloma Patients Europe (MPE) with the aim of exploring patient and doctor (haematologist) experiences of myeloma diagnosis. MPE ran a survey, and several focus groups and interviews, in which more than 600…

MPE endorses the International COVID-19 Blood Cancer Coalition’s (ICBCC) patient impact statement

A multi-stakeholder coalition consisting of more than 60 representatives from the global patient advocacy and clinical community has formed the International COVID-19 Blood Cancer Coalition (ICBCC) to address the specific impact of the pandemic on immunocompromised blood cancer patients and to recommend solutions and actions to mitigate those risks. The special vulnerability of those with blood cancers and others needs to be addressed in a proactive way. While we need to be prepared for surprises…

MPE support for Ukrainian myeloma and AL amyloidosis patients

Myeloma Patients Europe (MPE) is here to support Ukrainian patients during this ongoing crisis. If you are a myeloma or AL amyloidosis patient in Ukraine or a refugee in another European country and in need of information on how to access treatment and support, please contact us at .